Invivyd 

$1.32
136
-$0.02-1.13% Today

Statistics

Day High
1.34
Day Low
1.28
52W High
3.07
52W Low
0.46
Volume
1,579,743
Avg. Volume
2,838,518
Mkt Cap
306.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.51
-0.33
-0.16
0.02
Expected EPS
-0.030475
Actual EPS
N/A

Financials

-669.42%Profit Margin
Unprofitable
2021
2022
2023
2024
50.77MRevenue
-339.85MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVVD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the development of monoclonal antibodies for the treatment of various diseases, similar to Invivyd's focus on antibody therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the research and development of antiviral drugs, directly competing with Invivyd's efforts in infectious disease treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Invivyd in the development of treatments for infections and diseases, including their work on vaccines and antibody therapies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a direct competitor in the pharmaceutical and biotechnology industry, with a broad portfolio that includes treatments for infectious diseases, competing with Invivyd's focus.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is involved in the creation of vaccines and therapeutic antibodies, competing with Invivyd in the infectious disease space.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories competes with Invivyd through its diagnostic and medical devices for infectious diseases, as well as its pharmaceutical products.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for infectious diseases, which puts it in competition with Invivyd's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb competes in the biopharmaceutical field, focusing on innovative medicines that include infectious disease treatments, similar to Invivyd's focus.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of drugs for infectious diseases, directly competing with Invivyd.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes with Invivyd in the global healthcare market, particularly in the development of vaccines and treatments for infectious diseases.

About

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Show more...
CEO
Mr. William E. Duke Jr., M.B.A.
Employees
99
Country
US
ISIN
US00534A1025

Listings

0 Comments

Share your thoughts

FAQ

What is Invivyd stock price today?
The current price of IVVD is $1.32 USD — it has decreased by -1.13% in the past 24 hours. Watch Invivyd stock price performance more closely on the chart.
What is Invivyd stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Invivyd stocks are traded under the ticker IVVD.
Is Invivyd stock price growing?
IVVD stock has fallen by -13.25% compared to the previous week, the month change is a -23.84% fall, over the last year Invivyd has showed a +126.21% increase.
What is Invivyd market cap?
Today Invivyd has the market capitalization of 306.56M
When is the next Invivyd earnings date?
Invivyd is going to release the next earnings report on May 07, 2026.
What were Invivyd earnings last quarter?
IVVD earnings for the last quarter are 0.02 USD per share, whereas the estimation was -0.08 USD resulting in a +124.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Invivyd revenue for the last year?
Invivyd revenue for the last year amounts to 50.77M USD.
What is Invivyd net income for the last year?
IVVD net income for the last year is -339.85M USD.
How many employees does Invivyd have?
As of April 02, 2026, the company has 99 employees.
In which sector is Invivyd located?
Invivyd operates in the Health Care sector.
When did Invivyd complete a stock split?
Invivyd has not had any recent stock splits.
Where is Invivyd headquartered?
Invivyd is headquartered in Waltham, US.